# Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO)

> Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) trades at $5.72 (+0.35%) as of 3:41:40 PM EST on Nov 10, 2026, -2.71% over the past month. Market cap is $350.28M, with 9.7 days to cover in short interest.

Canonical: https://massive.com/quote/obio
Data as of: 2026-11-10T20:41:40.136Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$5.72** +0.02 (+0.35%)
As of 3:41:40 PM EST on Nov 10, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.88% |
| 1W | +3.42% |
| 1M | -2.71% |
| YTD | +38.55% |
| 1Y | +40.24% |
| 52-wk range | $3.46 – $6.50 |

From daily closes through Nov 10, 2026.

## Key statistics

Today's trading snapshot for OBIO: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $5.69 – $5.91 |
| Open | $5.83 |
| Prev close | $5.70 |
| Volume | 288.09K |
| Market cap | $350.28M |
| Shares out | 61.45M |

## Valuation and profitability ratios

Valuation and profitability ratios for Orchestra BioMed Holdings, Inc. Ordinary Shares: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 10.95 |
| P/B | 18.13 |
| P/FCF | — |
| ROE | -308.3% |
| ROA | -51.5% |
| Debt/Equity | 1.80 |
| Div yield | 0.00% |

As of Nov 9, 2026

## Insider trading

[Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) insider trading](https://massive.com/quote/obio/insider-trading.md): open-market Form 4 buys and sells by Orchestra BioMed Holdings, Inc. Ordinary Shares insiders over the last 12 months.

## 8-K filings

Material corporate events Orchestra BioMed Holdings, Inc. Ordinary Shares has disclosed to the SEC on Form 8-K.

- Nov 9, 2026 · Underwriting agreement
  “On November 5, 2026, Orchestra BioMed Holdings, Inc. entered into an underwriting agreement with Piper Sandler & Co. and TD Securities (USA) LLC as representatives of the several underwriters named therein. The Underwriting Agreement contains customary representations, warranties and covenants, indemnification provisions and termination provisions.”
- Oct 1, 2026 · Partnership or collaboration
  “The BACKBEAT Trial is being conducted with Medtronic plc (NYSE: MDT), the Company's strategic collaborator for the BACKBEAT Trial and, subject to regulatory approval, for the commercialization of AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension despite the use of medication.”
- Sep 8, 2026 · Investor presentation
  “A copy of a slide presentation that Orchestra BioMed Holdings, Inc. (the "Company") uses at investor and industry conferences and presentations is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure. Additionally, the Company has posted the slide presentation on its website at https://investors.orchestrabiomed.com under the Investor Relations section.”
- Jun 23, 2026 · Annual meeting results
  “On June 23, 2026, Orchestra BioMed Holdings, Inc. held its 2026 Annual Meeting of Stockholders. Based on the votes set forth above, the Company's stockholders elected each of the three nominees set forth above to serve as a Class III director of the Company until the Company's 2029 annual meeting of stockholders and until such director's respective successor is duly elected and qualified.”
- Feb 13, 2026 · Executive compensation change
  “On February 12, 2026, the Board also approved a revised restricted stock unit ('RSU') vesting schedule, under which RSU awards will vest over three years in four equal installments: 25% at 18 months, 25% at 24 months, 25% at 30 months, and 25% at 36 months.”

## OBIO short interest

How heavily OBIO is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 9.7 |
| Short interest | 2.55M |
| Avg volume | 263.11K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## OBIO news

The latest news and headlines about Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO).

- [Orchestra BioMed Announces Pricing of Public Offering](https://www.globenewswire.com/news-release/2026/11/06/3397296/0/en/orchestra-biomed-announces-pricing-of-public-offering.html) · GlobeNewswire Inc. · Nov 5, 2026 · positive sentiment
- [Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates](https://www.zacks.com/stock/news/3025109/guardant-health-gh-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3025109) · Zacks Investment Research · Nov 5, 2026 · neutral sentiment
- [Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes](https://www.globenewswire.com/news-release/2026/06/29/3318888/0/en/Orchestra-BioMed-Joins-Russell-3000-and-Russell-2000-Indexes.html) · GlobeNewswire Inc. · Jun 29, 2026 · positive sentiment
- [Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences](https://www.globenewswire.com/news-release/2026/02/19/3241015/0/en/Orchestra-BioMed-to-Participate-in-Upcoming-Institutional-Investor-Conferences.html) · GlobeNewswire Inc. · Feb 19, 2026 · positive sentiment
- [Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial](https://www.globenewswire.com/news-release/2025/10/27/3174623/0/en/Orchestra-BioMed-Announces-First-Patients-Enrolled-in-Virtue-SAB-US-Pivotal-IDE-Coronary-Trial.html) · GlobeNewswire Inc. · Oct 27, 2025 · positive sentiment

## About Orchestra BioMed Holdings, Inc. Ordinary Shares

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 86 |
| Listed | Jan 27, 2023 |

[Company website](https://www.orchestrabiomed.com)

## FAQ

### What is the Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) stock price today?

Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) is trading at $5.72 (+0.35% on the day) as of 3:41:40 PM EST on Nov 10, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Orchestra BioMed Holdings, Inc. Ordinary Shares?

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies.

### What is the short interest in OBIO?

As of Oct 15, 2026, OBIO has 2.55M shares short and 9.7 days to cover.

### What exchange is OBIO listed on?

Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) trades on Nasdaq in USD, in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry.

## Live data

Prices here are 15-minute delayed. For real-time OBIO quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=OBIO`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) insider trading](https://massive.com/quote/obio/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms